Immunitybio Inc ((IBRX)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: ImmunityBio, Inc. is conducting a Phase 2, open-label, single-arm study titled A Phase 2, Open-label, Single-arm Study Of Autologous Memory Cytokine Enriched Natural Killer (M-CENK) Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer. The study aims to evaluate the safety and preliminary efficacy of this combination therapy in treating platinum-resistant high-grade ovarian cancer, a condition with limited treatment options.
Intervention/Treatment: The study tests a combination of treatments: Gemcitabine, a chemotherapy drug; N-803, an IL-15 superagonist; and M-CENK, an adoptive cell therapy. This combination is designed to enhance the immune response against cancer cells.
Study Design: This interventional study follows a single-group assignment model without masking, focusing on treatment as its primary purpose. Participants receive Gemcitabine, N-803, and M-CENK in a structured regimen.
Study Timeline: The study began on November 6, 2024, with the latest update on July 7, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
Market Implications: The study’s progress could impact ImmunityBio’s stock performance positively, as successful results may enhance investor confidence. This development is particularly significant in the competitive oncology market, where innovative treatments are highly valued.
The study is ongoing, with further details available on the ClinicalTrials portal.